BioCentury | Jun 30, 2014
Company News

Edimer, InformedDNA deal

...ectodermal dysplasia (XLHED) in which InformedDNA may identify individuals that may benefit from treatment with Edimer’s...
...in the U.S. and EU and Fast Track designation in the U.S. for the indication. Edimer Pharmaceuticals Inc....
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

...December 2012 and in the $18 million series B round for fellow rare disease company Edimer...
BioCentury | Nov 4, 2013
Finance

Investing by design

...a $75 million series B round for Ultragenyx Pharmaceutical Inc. in December 2012 and in Edimer Pharmaceuticals Inc....
...inhibitors, which can reestablish the immune system's ability to detect tumors. Companies and Institutions Mentioned Edimer Pharmaceuticals Inc....
BioCentury | Oct 14, 2013
Clinical News

Fc-EDA1: Phase II started

...in the U.S. and EU and Fast Track designation in the U.S. for the indication. Edimer Pharmaceuticals Inc....
BioCentury | Aug 5, 2013
Company News

Edimer board of directors update

Edimer Pharmaceuticals Inc. , Cambridge, Mass. Business: Dermatology, Autoimmune Appointed: David Mott, general partner at New Enterprise Associates WIR Staff autoimmune Dermatology...
BioCentury | Aug 5, 2013
Financial News

Edimer completes venture financing

Edimer Pharmaceuticals Inc. , Cambridge, Mass. Business: Dermatology, Autoimmune Date completed: 7/30/13 Type: Venture financing Raised: $18 million Investors: New Enterprise Associates (NEA); Sanofi-Genzyme BioVentures; Third Rock Ventures; VI Partners Note: The financing is a tranched...
BioCentury | Jul 31, 2013
Financial News

Edimer secures $18M in series B

...existing investors Third Rock Ventures and VI Partners. NEA's David Mott will join Edimer's board. Edimer's...
BioCentury | Oct 8, 2012
Company News

Momenta, Sialix deal

...Jeff Behrens as CEO. He was previously senior director of business development and operations at Edimer Pharmaceuticals Inc....
BioCentury | Oct 6, 2012
Company News

Sialix in deal with Momenta

...Jeff Behrens as CEO. He was previously senior director of business development and operations at Edimer Pharmaceuticals Inc....
BioCentury | Aug 27, 2012
Emerging Company Profile

Edimer: Gland idea

...Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of...
...administration of EDI200 in the mouse model permanently corrected the XLHED phenotype. Kirby noted that Edimer...
...programs and opted to lead Edimer's $22 million series A round in 2009. Kirby said Edimer...
Items per page:
1 - 10 of 12
BioCentury | Jun 30, 2014
Company News

Edimer, InformedDNA deal

...ectodermal dysplasia (XLHED) in which InformedDNA may identify individuals that may benefit from treatment with Edimer’s...
...in the U.S. and EU and Fast Track designation in the U.S. for the indication. Edimer Pharmaceuticals Inc....
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

...December 2012 and in the $18 million series B round for fellow rare disease company Edimer...
BioCentury | Nov 4, 2013
Finance

Investing by design

...a $75 million series B round for Ultragenyx Pharmaceutical Inc. in December 2012 and in Edimer Pharmaceuticals Inc....
...inhibitors, which can reestablish the immune system's ability to detect tumors. Companies and Institutions Mentioned Edimer Pharmaceuticals Inc....
BioCentury | Oct 14, 2013
Clinical News

Fc-EDA1: Phase II started

...in the U.S. and EU and Fast Track designation in the U.S. for the indication. Edimer Pharmaceuticals Inc....
BioCentury | Aug 5, 2013
Company News

Edimer board of directors update

Edimer Pharmaceuticals Inc. , Cambridge, Mass. Business: Dermatology, Autoimmune Appointed: David Mott, general partner at New Enterprise Associates WIR Staff autoimmune Dermatology...
BioCentury | Aug 5, 2013
Financial News

Edimer completes venture financing

Edimer Pharmaceuticals Inc. , Cambridge, Mass. Business: Dermatology, Autoimmune Date completed: 7/30/13 Type: Venture financing Raised: $18 million Investors: New Enterprise Associates (NEA); Sanofi-Genzyme BioVentures; Third Rock Ventures; VI Partners Note: The financing is a tranched...
BioCentury | Jul 31, 2013
Financial News

Edimer secures $18M in series B

...existing investors Third Rock Ventures and VI Partners. NEA's David Mott will join Edimer's board. Edimer's...
BioCentury | Oct 8, 2012
Company News

Momenta, Sialix deal

...Jeff Behrens as CEO. He was previously senior director of business development and operations at Edimer Pharmaceuticals Inc....
BioCentury | Oct 6, 2012
Company News

Sialix in deal with Momenta

...Jeff Behrens as CEO. He was previously senior director of business development and operations at Edimer Pharmaceuticals Inc....
BioCentury | Aug 27, 2012
Emerging Company Profile

Edimer: Gland idea

...Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of...
...administration of EDI200 in the mouse model permanently corrected the XLHED phenotype. Kirby noted that Edimer...
...programs and opted to lead Edimer's $22 million series A round in 2009. Kirby said Edimer...
Items per page:
1 - 10 of 12